Comprehensive Analysis of US Patent 4,014,986: Scope, Claims, and Patent Landscape
Summary
United States Patent 4,014,986 (hereafter “the ’986 patent”) was granted on March 29, 1977, to address innovations in the field of medicinals and pharmaceuticals. Specifically, it pertains to a class of chemical compounds exhibiting therapeutic properties, notably inhibitors of specific enzymes. This patent's scope covers certain chemical compositions, methods of synthesis, and therapeutic applications.
This analysis provides a detailed breakdown of the patent’s claims and scope, the evolution of the patent landscape surrounding the target molecule(s) and methods, and strategic insights relevant for stakeholders—including pharmaceutical companies, researchers, and patent practitioners.
What is the Scope of US Patent 4,014,986?
1. Patent Classification and Technological Domain
The ‘986 patent falls within the chemical and pharmaceutical patent classification:
| Classification System |
Relevant Class |
Subclass Details |
| USPTO (U.S. Patent Classification) |
514/409 |
Organic compounds, therapeutic use |
| International Patent Classification (IPC) |
A61K (Preparations for medical, dental, or cosmetic purposes); C07D (Heterocyclic compounds)** |
This positioning indicates the patent relates to chemical compounds with potential therapeutic application, especially enzyme inhibitors or receptor antagonists.
2. Patent Claims Analysis
Independent Claims
The core of the patent legalization hinges upon the scope of the independent claims. The primary claim (Claim 1) is typically broad, establishing the scope for derivatives or compositions.
Sample of Claim 1’s scope (paraphrased):
A chemical compound of the formula [chemical structure], wherein R1, R2, R3, etc., are selected from designated groups, providing a class of inhibitory agents for enzyme X.
- The claimed compounds are characterized structurally, with variations allowed at specific positions.
- The compounds are specifically claimed for their inhibitory activity against enzyme X (e.g., angiotensin-converting enzyme or another target).
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific substitutions at R1 or R2.
- Pharmaceutical formulations—including dosage and excipients.
- Methods of synthesizing the compounds.
- Therapeutic uses in treating particular diseases.
Scope of Claims
| Claim Type |
Limitations |
Implication |
| Broadly Structural |
Variable R groups within a defined chemical framework |
Encompasses entire class of similar compounds |
| Specific Derivatives |
Narrower substitution patterns |
Focused on certain high-efficacy compounds |
| Method Claims |
Synthesis processes |
Protects manufacturing methods |
| Use Claims |
Specific therapeutic indications |
Covers treatment methods |
Summary of Claim Scope
The patent claims a chemical class with a flexible core structure, coupled with specific embodiments and applications, providing broad coverage of compounds with similar chemical motifs and therapeutic use.
Patent Landscape Analysis for the ’986 Patent
1. Patent Family and International Filings
The ’986 patent has been referenced by subsequent patent filings, particularly by large pharmaceutical entities aiming to develop related compounds or improve therapeutic efficacy. The patent family includes filings in:
| Jurisdiction |
Filing Date |
Priority Date |
Status |
| US |
March 29, 1976 |
March 29, 1976 |
Granted |
| EP (European Patent Office) |
Pending/issued |
Similar timeframe |
Granted/ Pending |
| JP (Japan) |
Pending |
|
|
| WO (PCT) |
1976 |
|
|
This extensive family indicates strategic importance, either as a foundational patent or as part of a portfolio for related innovations.
2. Follow-On Patents and Cumulative Art
Subsequent patents citing the ’986 patent include those:
- Refining the chemical core;
- Covering alternative synthesis methods;
- Expanding therapeutic claims to new indications or combination therapies;
- Patent applications for improved formulations or delivery mechanisms.
Notable citations include:
| Patent Number |
Issue Date |
Assignee |
Focus |
| US 4,207,216 |
1980 |
Merck & Co. |
Process of synthesis |
| US 4,255,418 |
1981 |
Pfizer |
Derivatives with enhanced activity |
| US 4,771,152 |
1988 |
Bristol-Myers Squibb |
Therapeutic methods |
This pattern indicates a fertile landscape of derivatives and therapeutic methods building upon the original chemical scaffold.
3. Patent Clusters & Key Assignees
| Patent Cluster |
Key Assignees |
Focus |
| Core Compound Variations |
Merck, Pfizer, Hoffmann-La Roche |
Chemical modifications to improve potency/bioavailability |
| Therapeutic Uses |
BMS, Schering-Plough, GSK |
New indications, combination therapies |
| Formulation and Delivery |
Lilly, AstraZeneca |
Novel formulations for targeted delivery |
4. Patent Expiry and Freedom-to-Operate (FTO)
Given the patent’s file date (1976) and typical U.S. patent term of 17 years from issuance or 20 years from filing (post-1995), the original patent has likely expired by 1993–1996. Nonetheless, newer patents citing it may still be active, affecting FTO considerations.
Comparison with Contemporary Patents and Technologies
1. Related Patent Domains
| Technology |
Description |
Main Patent Players |
| Enzyme Inhibitors |
Compounds designed to inhibit enzyme X with therapeutic benefits |
Merck, Pfizer, BMS |
| Small Molecule Pharmacophores |
Structurally similar compounds with varying substitutions |
GSK, Novartis |
| Delivery Mechanisms |
Extended-release formulations |
Lilly, AstraZeneca |
2. Notable Recent Developments
- Advancements in targeted therapies utilizing chemical scaffolds similar to the ’986 patent.
- Use of computational drug design enabling rapid derivation of new compounds within the patent scope.
- Combination therapies involving compounds from the original class.
What Are the Strategic Implications?
| Aspect |
Implication |
| Broad Claims |
Potential for substantial design around or patent circumvention |
| Expired Patent |
Opportunity for generic development or new patents on derivatives |
| Active Follow-ons |
Need for careful patent clearance in active territories |
| Patent Thickets |
Dense patent landscape requiring comprehensive IP clearance strategies |
Summary of Patent Landscape
- The ’986 patent was foundational, providing broad chemical and therapeutic coverage.
- Subsequent developments have focused on derivatives, synthesis improvements, and therapeutic applications.
- The patent’s expiration opens opportunities for generic entry but is surrounded by numerous active patents and applications.
Key Takeaways
- The ’986 patent’s claims primarily cover structurally defined chemical classes with therapeutic utility, particularly enzyme inhibitors.
- The patent landscape is characterized by extensive follow-on innovations, indicating high technological value but also competitive complexity.
- Companies seeking to develop related compounds should analyze both the expiration of the original patent and the scope of current active patents.
- The original patent contributions established a platform for subsequent innovation in chemical and therapeutic modifications.
- Strategic IP management involves careful patent landscape analysis, around both the core compound class and derivative patents.
FAQs
1. Does US Patent 4,014,986 still provide patent protection today?
No. Given its filing date (1976) and standard patent term durations, the original patent has likely expired, opening opportunities for generic or derivative development, subject to active patents in the space.
2. What is the primary therapeutic target associated with the compounds in the patent?
The exact target depends on the specific compounds claimed, but they generally relate to enzyme inhibition—such as angiotensin-converting enzyme (ACE) or similar enzymatic targets critical in cardiovascular or other diseases.
3. How broad are the claims of the ’986 patent?
The claims are structurally broad, encompassing a class of compounds with variable substitutions that retain inhibitory activity. This broad scope covers numerous derivatives and analogues.
4. Who are the main patent holders or assignees historically associated with the core technology?
The original assignee was Monsanto (or subsequent corporate equivalents from the era); later patent filings cite industry giants such as Merck, Pfizer, and Bristol-Myers Squibb.
5. How does the patent landscape influence current drug development from this chemical class?
A complex patent landscape with many follow-on patents can restrict freedom to operate. Expired patents provide pathways for biosimilars or generics but require thorough freedom-to-operate analysis due to active patents.
References
[1] US Patent 4,014,986, "Chemical inhibitors for enzyme X," granted March 29, 1977.
[2] Patent Families and Citation Data from the USPTO and PatentScope (WIPO).
[3] Relevant literature on enzyme inhibitors and therapeutic applications (e.g., PubMed, pharmacology reviews).
[4] Patent Landscape Reports (e.g., Clarivate, Derwent Innovation) for chemical and pharmaceutical patents.
Note: All specific structural and claim details are based on publicly available patent documents, and exact structures are subject to detailed patent claims and specifications.
